GlassScriptPhysician profile
Gary A Spector
NPI 1093816175
$32,400.10
in general payments reported to CMS, 2019-2025
66 companies · $2,422 in 2025
The $2,422 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,515 · 2020: $2,451 · 2021: $4,010 · 2022: $3,309 · 2023: $4,038 · 2024: $14K · 2025: $2,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $9,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,316.10 |
| Consulting Fee | $9,800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $11,265.71 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $5,818.58 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,506.02 | 2019-2025 | Jardiance |
| Abbvie INC. | $2,504.05 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $1,335.35 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $1,203.58 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $919.89 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $525.71 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Pfizer INC. | $508.02 | 2019-2025 | |
| Inspire Medical Systems, INC. | $389.66 | 2023-2025 | Inspire |
| Amgen INC. | $381.02 | 2019-2025 | Otezla, Repatha, Repatha |
| Allergan, INC. | $338.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.18 | 2019-2024 | Trintellix |
| Amarin Pharma, INC. | $292.32 | 2019-2021 | |
| Abbott Laboratories | $277.21 | 2019-2023 | Freestyle Libre 3 |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Spector listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.